Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 185

1.

Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease.

Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA.

Expert Opin Investig Drugs. 2019 Oct;28(10):861-869. doi: 10.1080/13543784.2019.1667333. Epub 2019 Sep 26. Review.

PMID:
31513439
2.

Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration-Approved Gene Therapy and Implications for Future One-Time Therapies.

Buessing M, O'Connell T, Johnson S, Pitluck S, Ciulla TA.

Value Health. 2019 Aug;22(8):970-971. doi: 10.1016/j.jval.2018.12.013. Epub 2019 May 25. No abstract available.

PMID:
31426938
3.

Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery.

Wentz SM, Price F, Harris A, Siesky B, Ciulla T.

Expert Opin Pharmacother. 2019 Oct;20(14):1703-1709. doi: 10.1080/14656566.2019.1645834. Epub 2019 Jul 25.

PMID:
31343372
4.

Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49‚ÄČ485 Eyes.

Ciulla TA, Hussain RM, Pollack JS, Williams DF.

Ophthalmol Retina. 2019 May 25. pii: S2468-6530(19)30280-5. doi: 10.1016/j.oret.2019.05.017. [Epub ahead of print]

PMID:
31324588
5.

Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease.

Johnson S, Buessing M, O'Connell T, Pitluck S, Ciulla TA.

JAMA Ophthalmol. 2019 Jul 18. doi: 10.1001/jamaophthalmol.2019.2512. [Epub ahead of print]

6.

Innovative therapies for neovascular age-related macular degeneration.

Al-Khersan H, Hussain RM, Ciulla TA, Dugel PU.

Expert Opin Pharmacother. 2019 Oct;20(15):1879-1891. doi: 10.1080/14656566.2019.1636031. Epub 2019 Jul 12.

PMID:
31298960
7.

Vascular dysfunction in retinitis pigmentosa.

Lang M, Harris A, Ciulla TA, Siesky B, Patel P, Belamkar A, Mathew S, Verticchio Vercellin AC.

Acta Ophthalmol. 2019 Nov;97(7):660-664. doi: 10.1111/aos.14138. Epub 2019 May 17. Review.

PMID:
31099494
8.

Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States.

Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC.

Ophthalmol Retina. 2018 Jul;2(7):645-653. doi: 10.1016/j.oret.2018.01.006. Epub 2018 Mar 1.

PMID:
31047372
9.

Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States.

Ciulla TA, Bracha P, Pollack J, Williams DF.

Ophthalmol Retina. 2018 Dec;2(12):1179-1187. doi: 10.1016/j.oret.2018.06.004. Epub 2018 Jul 29.

PMID:
31047187
10.

Complement inhibition as a therapeutic strategy in retinal disorders.

Kassa E, Ciulla TA, Hussain RM, Dugel PU.

Expert Opin Biol Ther. 2019 Apr;19(4):335-342. doi: 10.1080/14712598.2019.1575358. Epub 2019 Feb 11.

PMID:
30686077
11.

Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy.

Lloyd A, Piglowska N, Ciulla T, Pitluck S, Johnson S, Buessing M, O'Connell T.

Br J Ophthalmol. 2019 Nov;103(11):1610-1614. doi: 10.1136/bjophthalmol-2018-313089. Epub 2019 Jan 18.

12.

Vital Dyes in Vitreomacular Surgery.

Bracha P, Ciulla TA, Baumal CR.

Ophthalmic Surg Lasers Imaging Retina. 2018 Oct 1;49(10):788-798. doi: 10.3928/23258160-20181002-07. Review.

PMID:
30395665
13.

Stargardt macular dystrophy and evolving therapies.

Hussain RM, Ciulla TA, Berrocal AM, Gregori NZ, Flynn HW Jr, Lam BL.

Expert Opin Biol Ther. 2018 Oct;18(10):1049-1059. doi: 10.1080/14712598.2018.1513486. Epub 2018 Sep 10. Review.

PMID:
30129371
14.

Pharmacotherapy of retinal disease with visual cycle modulators.

Hussain RM, Gregori NZ, Ciulla TA, Lam BL.

Expert Opin Pharmacother. 2018 Apr;19(5):471-481. doi: 10.1080/14656566.2018.1448060. Epub 2018 Mar 15. Review.

PMID:
29542350
15.

Gene therapy for inherited retinal and optic nerve degenerations.

Moore NA, Morral N, Ciulla TA, Bracha P.

Expert Opin Biol Ther. 2018 Jan;18(1):37-49. doi: 10.1080/14712598.2018.1389886. Epub 2017 Oct 23. Review.

PMID:
29057663
16.

Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency.

Hussain RM, Hariprasad SM, Ciulla TA.

Ophthalmic Surg Lasers Imaging Retina. 2017 Oct 1;48(10):780-784. doi: 10.3928/23258160-20170928-01. Review. No abstract available.

PMID:
29020420
17.

The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review.

Bracha P, Moore NA, Ciulla TA, WuDunn D, Cantor LB.

Surv Ophthalmol. 2018 May - Jun;63(3):281-295. doi: 10.1016/j.survophthal.2017.08.008. Epub 2017 Sep 5. Review.

PMID:
28882597
18.

Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.

Hussain RM, Ciulla TA.

Expert Opin Emerg Drugs. 2017 Sep;22(3):235-246. doi: 10.1080/14728214.2017.1362390. Epub 2017 Aug 4. Review.

PMID:
28756707
19.

Gene therapy for age-related macular degeneration.

Moore NA, Bracha P, Hussain RM, Morral N, Ciulla TA.

Expert Opin Biol Ther. 2017 Oct;17(10):1235-1244. doi: 10.1080/14712598.2017.1356817. Epub 2017 Jul 20. Review.

PMID:
28726562
20.

LEAN SIX SIGMA TECHNIQUES TO IMPROVE OPHTHALMOLOGY CLINIC EFFICIENCY.

Ciulla TA, Tatikonda MV, ElMaraghi YA, Hussain RM, Hill AL, Clary JM, Hattab E.

Retina. 2018 Sep;38(9):1688-1698. doi: 10.1097/IAE.0000000000001761.

PMID:
28723845

Supplemental Content

Loading ...
Support Center